MX2022013466A - Agentes de union a ilt y metodos para su uso. - Google Patents
Agentes de union a ilt y metodos para su uso.Info
- Publication number
- MX2022013466A MX2022013466A MX2022013466A MX2022013466A MX2022013466A MX 2022013466 A MX2022013466 A MX 2022013466A MX 2022013466 A MX2022013466 A MX 2022013466A MX 2022013466 A MX2022013466 A MX 2022013466A MX 2022013466 A MX2022013466 A MX 2022013466A
- Authority
- MX
- Mexico
- Prior art keywords
- binding agents
- methods
- ilt
- ilt2
- ilt4
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063019068P | 2020-05-01 | 2020-05-01 | |
| US202063122848P | 2020-12-08 | 2020-12-08 | |
| PCT/US2021/029866 WO2021222544A1 (en) | 2020-05-01 | 2021-04-29 | Ilt-binding agents and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013466A true MX2022013466A (es) | 2022-11-16 |
Family
ID=76012027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013466A MX2022013466A (es) | 2020-05-01 | 2021-04-29 | Agentes de union a ilt y metodos para su uso. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11802155B2 (https=) |
| EP (2) | EP4691561A2 (https=) |
| JP (1) | JP7834028B2 (https=) |
| KR (1) | KR20230005978A (https=) |
| CN (2) | CN115768524A (https=) |
| AU (1) | AU2021265801B2 (https=) |
| BR (1) | BR112022021684A2 (https=) |
| CA (1) | CA3181197A1 (https=) |
| CL (1) | CL2022003004A1 (https=) |
| CO (1) | CO2022015208A2 (https=) |
| ES (1) | ES3039441T3 (https=) |
| IL (1) | IL297748A (https=) |
| MX (1) | MX2022013466A (https=) |
| MY (1) | MY209480A (https=) |
| PE (1) | PE20221894A1 (https=) |
| TW (1) | TW202206463A (https=) |
| WO (1) | WO2021222544A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111867614A (zh) * | 2018-01-18 | 2020-10-30 | 艾达奈特公司 | 抗lilrb抗体及其用途 |
| JP7284256B2 (ja) | 2019-08-12 | 2023-05-30 | ビオンド バイオロジクス リミテッド | Ｉｌｔ２に対する抗体およびその使用 |
| JP2023537396A (ja) | 2020-08-12 | 2023-08-31 | ビオンド バイオロジクス リミテッド | Ｉｌｔ２に対する抗体およびその使用 |
| WO2023077521A1 (en) * | 2021-11-08 | 2023-05-11 | Celldex Therapeutics, Inc | Anti-ilt4 and anti-pd-1 bispecific constructs |
| WO2023140875A1 (en) * | 2022-01-19 | 2023-07-27 | Ngm Biopharmaceuticals, Inc. | Uses of ilt3-binding agents |
| IL315487A (en) * | 2022-03-07 | 2024-11-01 | Agenus Inc | ANTI-ILT2 antibodies and their uses |
| WO2023170434A1 (en) | 2022-03-11 | 2023-09-14 | Macomics Limited | Compositions and methods for modulation of macrophage activity |
| WO2023235706A1 (en) * | 2022-05-31 | 2023-12-07 | Ngm Biopharmaceuticals, Inc. | Combination therapies using ilt-binding agents and pd-1 inhibitors |
| WO2024120526A1 (zh) * | 2022-12-09 | 2024-06-13 | 诺纳生物（苏州）有限公司 | 抗ilt4抗体及其制备方法和应用 |
| AU2023410277A1 (en) * | 2022-12-23 | 2025-06-12 | Iomx Therapeutics Ag | Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof |
| EP4491230A1 (en) * | 2023-07-14 | 2025-01-15 | iOmx Therapeutics AG | Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof |
| WO2024218650A1 (en) * | 2023-04-19 | 2024-10-24 | Pfizer Inc. | Lilrb1 and lilrb2 antibodies and methods of use thereof |
| WO2025059304A2 (en) * | 2023-09-12 | 2025-03-20 | Agenus Inc. | Methods of treating cancer using ilt2 antibodies and combination therapies |
| GB202314087D0 (en) * | 2023-09-14 | 2023-11-01 | Macomics Ltd | Biomarker for cancer |
| WO2025168070A1 (zh) * | 2024-02-08 | 2025-08-14 | 东曜药业有限公司 | 一种抗ilt2/4单抗的制剂、包含其的药盒及其应用 |
| WO2025191142A2 (en) | 2024-03-15 | 2025-09-18 | Les Laboratoires Servier | Antibodies to lilrb1 and lilrb2 and compositions thereof |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE456656T1 (de) | 1996-12-06 | 2010-02-15 | Schering Corp | Isolierte gene aus säuger monozyten und betreffende reagentien |
| US20060078564A1 (en) | 2002-05-08 | 2006-04-13 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
| US6448035B1 (en) | 1997-04-24 | 2002-09-10 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR) |
| US6384203B1 (en) | 1999-05-12 | 2002-05-07 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
| US20040241167A1 (en) | 2001-06-25 | 2004-12-02 | Nicole Suciu-Foca | Ilt3 and ilt4-related compositons and methods |
| WO2003000199A2 (en) | 2001-06-25 | 2003-01-03 | The Trustees Of Columbia University In The City Of New York | Ilt3 and ilt4-related compositions and methods |
| PL374463A1 (en) | 2001-11-14 | 2005-10-17 | Immunex Corporation | Modulation of lir function to treat rheumatoid arthritis |
| WO2005100998A2 (en) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
| CA2637786A1 (en) | 2006-01-23 | 2007-08-16 | President And Fellows Of Harvard College | Compositions and methods for enhancing neuronal plasticity and regeneration |
| ES2437110T3 (es) | 2006-11-14 | 2014-01-08 | Genentech, Inc. | Moduladores de la regeneración neuronal |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| RU2010128608A (ru) | 2007-12-11 | 2012-01-20 | Дженентек, Инк. (Us) | Модуляторы регенерации нейронов |
| CL2009001155A1 (es) | 2008-05-13 | 2010-06-04 | Genentech Inc | Anticuerpo anti-pirb/lilrb aislado; polinucleotido que lo codifica; vector; celula huesped; metodo de obtencion; composicion farmaceutica que lo comprende; kit; y su uso para tratar enfermedades neurodegenerativas. |
| WO2009140361A1 (en) | 2008-05-13 | 2009-11-19 | Genentech, Inc. | ANTI-PirB ANTIBODIES |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| US20150174203A1 (en) | 2012-05-30 | 2015-06-25 | Icahn School Of Medicine At Mount Sinai | Compositions And Methods For Modulating Pro-Inflammatory Immune Response |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| WO2014116846A2 (en) | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| WO2014164519A1 (en) | 2013-03-12 | 2014-10-09 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for inhibiting the effects of amyloid beta oligomers |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| US9580504B1 (en) | 2013-11-07 | 2017-02-28 | Curetech Ltd. | Pidilizumab monoclonal antibody therapy following stem cell transplantation |
| CA2948871A1 (en) | 2014-05-22 | 2015-11-26 | Fred Hutchinson Cancer Research Center | Lilrb2 and notch-mediated expansion of hematopoietic precursor cells |
| WO2016044022A1 (en) | 2014-09-16 | 2016-03-24 | The Board Of Trustees Of The Leland Stanford Junior University | Blocking pirb upregulates spines and functional synapses to unlock visual cortical plasticity and facilitate recovery from amblyopia |
| WO2016111947A2 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| US20180201676A1 (en) | 2015-02-11 | 2018-07-19 | University Health Network | Methods and compositions for modulating lilr proteins |
| CA2977544C (en) | 2015-03-06 | 2023-12-19 | The Board Of Regents Of The University Of Texas System | Anti-lilrb antibodies and their use in detecting and treating cancer |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2017042814A1 (en) | 2015-09-10 | 2017-03-16 | Yeda Research And Development Co. Ltd. | Use of perforin positive immature dendritic cells in disease treatment |
| US20190177391A1 (en) | 2016-03-31 | 2019-06-13 | Baylor Research Institute | Angiopoietin-like protein 8 (angptl8) |
| WO2018027197A1 (en) | 2016-08-04 | 2018-02-08 | Memorial Sloan-Kettering Cancer Center | Cancer antigen targets and uses thereof |
| TWI796329B (zh) | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | 抗－ilt4抗體及抗原結合片段 |
| CN111712518B (zh) | 2017-11-17 | 2025-03-25 | 默沙东有限责任公司 | 对免疫球蛋白样转录物3(ilt3)具有特异性的抗体及其用途 |
| WO2019107387A1 (ja) | 2017-11-28 | 2019-06-06 | 国立大学法人大阪大学 | マラリア治療薬、マラリアの治療方法、マラリア治療用候補物質のスクリーニング方法、マラリア重症化マーカー、マラリアの重症化の危険度を試験する方法および試験試薬 |
| EA202091540A1 (ru) | 2017-12-22 | 2021-03-22 | Джаунс Терапьютикс, Инк. | Антитела к lilrb2 |
| CN111867614A (zh) * | 2018-01-18 | 2020-10-30 | 艾达奈特公司 | 抗lilrb抗体及其用途 |
| CN113056483B (zh) | 2018-07-09 | 2025-08-01 | 戊瑞治疗有限公司 | 结合到ilt4的抗体 |
| US20210301020A1 (en) | 2018-07-24 | 2021-09-30 | Amgen Inc. | Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors |
| PH12022551462A1 (en) | 2019-12-19 | 2023-11-13 | Ngm Biopharmaceuticals Inc | Ilt3-binding agents and methods of use thereof |
| CN114945594B (zh) | 2019-12-23 | 2024-11-26 | 株式会社Lg化学 | 抗lilrb1抗体及其用途 |
-
2021
- 2021-04-29 MY MYPI2022005825A patent/MY209480A/en unknown
- 2021-04-29 AU AU2021265801A patent/AU2021265801B2/en active Active
- 2021-04-29 CN CN202180045295.2A patent/CN115768524A/zh active Pending
- 2021-04-29 ES ES21726775T patent/ES3039441T3/es active Active
- 2021-04-29 BR BR112022021684A patent/BR112022021684A2/pt unknown
- 2021-04-29 PE PE2022002422A patent/PE20221894A1/es unknown
- 2021-04-29 WO PCT/US2021/029866 patent/WO2021222544A1/en not_active Ceased
- 2021-04-29 US US17/244,169 patent/US11802155B2/en active Active
- 2021-04-29 IL IL297748A patent/IL297748A/en unknown
- 2021-04-29 CN CN202310455554.XA patent/CN116589581A/zh active Pending
- 2021-04-29 JP JP2022565860A patent/JP7834028B2/ja active Active
- 2021-04-29 CA CA3181197A patent/CA3181197A1/en active Pending
- 2021-04-29 KR KR1020227042267A patent/KR20230005978A/ko active Pending
- 2021-04-29 MX MX2022013466A patent/MX2022013466A/es unknown
- 2021-04-29 EP EP25191395.0A patent/EP4691561A2/en active Pending
- 2021-04-29 EP EP21726775.6A patent/EP4143229B1/en active Active
- 2021-04-30 TW TW110115745A patent/TW202206463A/zh unknown
-
2022
- 2022-10-26 CO CONC2022/0015208A patent/CO2022015208A2/es unknown
- 2022-10-27 CL CL2022003004A patent/CL2022003004A1/es unknown
-
2023
- 2023-09-13 US US18/466,722 patent/US12410251B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023523628A (ja) | 2023-06-06 |
| EP4143229B1 (en) | 2025-07-30 |
| JP7834028B2 (ja) | 2026-03-23 |
| EP4143229A1 (en) | 2023-03-08 |
| CO2022015208A2 (es) | 2023-01-16 |
| WO2021222544A1 (en) | 2021-11-04 |
| US12410251B2 (en) | 2025-09-09 |
| US11802155B2 (en) | 2023-10-31 |
| AU2021265801B2 (en) | 2026-04-02 |
| BR112022021684A2 (pt) | 2023-01-17 |
| AU2021265801A1 (en) | 2022-11-17 |
| CN116589581A (zh) | 2023-08-15 |
| CA3181197A1 (en) | 2021-11-04 |
| US20210355211A1 (en) | 2021-11-18 |
| IL297748A (en) | 2022-12-01 |
| CN115768524A (zh) | 2023-03-07 |
| CL2022003004A1 (es) | 2023-06-23 |
| ES3039441T3 (en) | 2025-10-21 |
| KR20230005978A (ko) | 2023-01-10 |
| US20240025997A1 (en) | 2024-01-25 |
| TW202206463A (zh) | 2022-02-16 |
| MY209480A (en) | 2025-07-11 |
| EP4691561A2 (en) | 2026-02-11 |
| PE20221894A1 (es) | 2022-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY209480A (en) | Ilt-binding agents and methods of use thereof | |
| PH12022551462A1 (en) | Ilt3-binding agents and methods of use thereof | |
| PH12020551997A1 (en) | Psma binding agents and uses thereof | |
| WO2021262597A3 (en) | Lair-1-binding agents and methods of use thereof | |
| PH12020551671A1 (en) | Chimeric receptors to dll3 and methods of use thereof | |
| ZA202206437B (en) | Claudin18.2 binding moieties and uses thereof | |
| MX2024000156A (es) | Proteinas de union a antigenos trem2 y usos de estas. | |
| PH12020500664A1 (en) | C3-binding agents and methods of use thereof | |
| PH12020552138A1 (en) | Bcma chimeric antigen receptors and uses thereof | |
| MX2021007939A (es) | Porciones de union a claudina 18.2 y usos de estas. | |
| MX392369B (es) | Anticuerpos anti-ilt4 y fragmentos de union a antigeno. | |
| CR20200341A (es) | Anticuerpos de unión a gprc5d | |
| PH12022550195A1 (en) | Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses | |
| ZA201706740B (en) | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) | |
| MX2023001727A (es) | Anticuerpos anti-c5 y usos de los mismos. | |
| PH12021551500A1 (en) | Anti-ctla4 antibodies and methods of use thereof | |
| GEP20237480B (en) | Antibodies against signal-regulatory protein alpha and methods of use | |
| SA519401370B1 (ar) | الأجسام المضادة وحيدة النسيلة المبتكرة لبروتين الموت المبرمج (pd-1) | |
| MY188362A (en) | Chimeric antigen receptors based on single-domain antibodies and methods of use thereof | |
| EP3812398A3 (en) | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 | |
| WO2015142675A3 (en) | Treatment of cancer using chimeric antigen receptor | |
| MX2022007635A (es) | Anticuerpos que se unen a hla-a2/mage-a4. | |
| SA521421049B1 (ar) | مستقبلات خيمرية لمستضدات بشروية ستة عبر الغشاء للبروستاتة 1 وطرق استخدامها | |
| PH12022552248A1 (en) | Anti-human cd19 antibodies | |
| CR20240139A (es) | Anticuerpos del receptor antitransferrina y usos de los mismos |